Risk factors for failure of Helicobacter pylori therapy — results of an individual data analysis of 2751 patients
- 19 December 2002
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 17 (1) , 99-109
- https://doi.org/10.1046/j.1365-2036.2003.01396.x
Abstract
Summary: Aim : To study risk factors for failure of Helicobacter pylori eradication treatment.Methods : Individual data from 2751 patients included in 11 multicentre clinical trials carried out in France and using a triple therapy, were gathered in a unique database. The 27 treatment regimens were regrouped into four categories.Results : The global failure rate was 25.8%[95% CI: 24–27]. There was a difference in failure rate between duodenal ulcer patients and non‐ulcer dyspeptic patients, 21.9% and 33.7%, respectively (P < 10−6). In a random‐effect model, the risk factors identified for eradication failure in duodenal ulcer patients (n = 1400) were: to be a smoker, and to have received the group 4 treatment, while to receive a 10 day treatment vs. 7 days protected from failure. In non‐ulcer dyspeptic patients (n = 913), the group 2 treatment was associated with failure. In both groups, age over 60 was associated with successful H. pylori eradication. There were less strains resistant to clarithromycin in duodenal ulcer patients than in non‐ulcer dyspeptic patients. Clarithromycin resistance predicted failure almost perfectly.Conclusion : Duodenal ulcer and non‐ulcer dyspeptic patients should be managed differently in medical practice and considered independently in eradication trials.Keywords
This publication has 27 references indexed in Scilit:
- cagA Status and Eradication Treatment Outcome of Anti- Helicobacter pylori Triple Therapies in Patients with Nonulcer DyspepsiaJournal of Clinical Microbiology, 2001
- How to Treat Heliobacter pyloriGastroenterology Clinics of North America, 2000
- Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatmentGut, 2000
- Absence of Benefit of EradicatingHelicobacter pyloriin Patients with Nonulcer DyspepsiaNew England Journal of Medicine, 1999
- A systematic review of Helicobacter pylori eradication therapy—the impact of antimicrobial resistance on eradication ratesAlimentary Pharmacology & Therapeutics, 1999
- One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH studyAlimentary Pharmacology & Therapeutics, 1999
- One week triple therapy for Helicobacter pylori: a multicentre comparative studyGut, 1997
- Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group.Gut, 1997
- Treatment of Helicobacter pylori infection with low or high dose omeprazole combined with amoxycillin and the effect of early retreatmentAlimentary Pharmacology & Therapeutics, 1996
- The Sydney System: Histological divisionJournal of Gastroenterology and Hepatology, 1991